Clinical trials: Cerebral Disorder
Intracranial Aneurysm
Enterprise Stent Aneurysm Treatment (ESAT) Study - France
The purpose of this study is to evaluate the morbidity, mortality, and efficacy of use of the Enterprise(TM) stent for the treatment of (ruptured or non-ruptured) intracranial aneurysms.
- Trial name
- ESAT (NCT00879580)
- Where
- 14 sites in France
- Volunteers
- 133 people
- Sponsor
- Codman & Shurtleff
Partial Epilepsies
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of 400 mg/day, or to a clinically effective lower dose for an individual patient, improves the tolerability and safety of lacosamide (200 mg…
- Trial name
- SELF (NCT01235403)
- Testing
- Lacosamide
- Where
- 32 sites in France
- Volunteers
- 100 people
- Sponsor
- UCB Pharma
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Migraine Headaches, Patent Foramen Ovale
PREMIUM Migraine Trial
The Purpose of this study is to evaluate the impact of percutaneous closure of a patent foramen ovale (PFO) (a hole in the heart), using the AMPLATZER PFO Occluder, on the incidence of migraine headaches.
- Trial name
- NCT00355056
- Testing
- AMPLATZER PFO Occluder
- Where
- 30 sites in United States
- Volunteers
- 230 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine
This is an observational, non-interventional and retrospective study in patients with advanced PD who have been treated with Rotigotine (Neupro®) as prescribed by physicians according to usual clinical practice in Spain.
- Trial name
- RETO-PD (NCT01504529)
- Where
- 59 sites in Spain
- Volunteers
- 391 people
- Sponsor
- UCB Pharma
Cerebral Palsy
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy
This is an Individual Patient Expanded Access Protocol of Autologous HB-adMSCs for the Treatment of Cerebral Palsy (CP) with the primary goal of treating 1 individual with CP who has exhausted all treatment options, his condition…
- Trial name
- NCT04029896
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Glioma, Glioblastoma
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to…
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT02717962
- Testing
- VAL-083, Dianhydrogalactitol
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Kintara Therapeutics, Inc.
Migraine Disorders
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects…
- Trial name
- GLADIATOR (NCT02565186)
- Testing
- Lasmiditan
- Where
- 196 sites in United States, Germany and 1 more
- Volunteers
- 2,171 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.
- Trial name
- NCT00939783
- Testing
- Dimebon
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Pfizer
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT00605683)
- Testing
- Safinamide (as add-on therapy)
- Where
- 125 sites in United States, Argentina and 18 more
- Volunteers
- 679 people
- Sponsor
- Newron Pharmaceuticals SPA
Brain and Central Nervous System Tumors
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells.
- Trial name
- NCT00107237
- Testing
- AEE788, everolimus
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Single centre, double-blind, randomised, placebo-controlled study of two dosage regimens of BIA 2-093 - 1800 mg (Group 1) and 2400 mg (Group 2) - in two groups of healthy male volunteers
- Trial name
- NCT01879345
- Testing
- BIA 2-093 - 1800 mg (Group 1), BIA 2-093 - 2400 mg (Group 2)
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Partial Seizures, Epilepsies, Partial
Once-A-Day Pregabalin For Partial Seizures
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs.
- Trial name
- NCT01262677
- Testing
- pregabalin
- Where
- 82 sites in United States, Argentina and 16 more
- Volunteers
- 325 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Carotid Artery Disease
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.
- Trial name
- CREATE (NCT00619775)
- Testing
- PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device
- Where
- 31 sites in United States
- Volunteers
- 419 people
- Sponsor
- Medtronic Endovascular
Adult Growth Hormone Deficiency
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
- Trial name
- NCT01909479
- Testing
- MOD-4023
- Where
- Israel
- Volunteers
- 202 people
- Sponsor
- OPKO Health, Inc.
Atherosclerosis
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated…
- Trial name
- CANTOS (NCT01327846)
- Testing
- Canakinumab, Standard of care
- Where
- 1,131 sites in United States, Argentina and 38 more
- Volunteers
- 10,066 people
- Sponsor
- Novartis Pharmaceuticals
Japanese Encephalitis
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj.
- Trial name
- BR-JELITE (NCT02532569)
- Testing
- Japanese encephalitis vaccine
- Where
- 9 sites in South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Focal Epilepsy
ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
This is a non interventional prospective study. Centers will enroll adult participants with partial onset seizures with or without secondary generalisation for whom the clinician has decided to initiate eslicarbazepine acetate…
- Trial name
- NCT03082222
- Where
- Germany
- Volunteers
- 246 people
- Sponsor
- Eisai GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.